Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.
about
Ocular Complications of Diabetes and Therapeutic ApproachesSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewA combined association test for rare variants using family and case-control data.Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: A pilot studyA Comparison of Food-grade Folium mori ( Sāng Yè) Extract and 1-Deoxynojirimycin for Glycemic Control and Renal Function in Streptozotocin-induced Diabetic Rats.Obesity in kidney disease: A heavyweight opponent.A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathySex-differences in renal expression of selected transporters and transcription factors in lean and obese Zucker spontaneously hypertensive fatty ratsObesity, metabolic syndrome and diabetic nephropathyIdentification of lead compounds for (99m)Tc and (18)F GPR91 radiotracersReactive Oxygen Species and Nuclear Factor Erythroid 2-Related Factor 2 Activation in Diabetic Nephropathy: A Hidden TargetHypertension Management in Diabetic Kidney DiseaseIncreased urinary Smad3 is significantly correlated with glomerular hyperfiltration and a reduced glomerular filtration rate and is a new urinary biomarker for diabetic nephropathy.Burden of Diabetes Related Complications Among Hypertensive and Non Hypertensive Diabetics: A Comparative StudyGLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Obesity and diabetic kidney disease.Diabetic Kidney Disease and Hypertension: A True Love Story.Effect of angiotensin converting enzyme inhibitor on glomerular hyperfiltration in patients with type 1 diabetes.The goal of blood pressure control for prevention of early diabetic microvascular complications.Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors.Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.Glucose Homeostasis and Cardiovascular Alterations in Diabetes.Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathyAngiotensinogen (AGT) gene missense polymorphisms (rs699 and rs4762) and diabetic nephropathy in Caucasians with type 2 diabetes mellitus.Obstetric and perinatal outcome in type 1 diabetes patients with diabetic nephropathy during 1988-2011.Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic Models.Allopurinol protects human glomerular endothelial cells from high glucose-induced reactive oxygen species generation, p53 overexpression and endothelial dysfunction.Effect of renin-angiotensin-aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis.Synergistic Interaction of Hypertension and Diabetes in Promoting Kidney Injury and the Role of Endoplasmic Reticulum Stress.Combining streptozotocin and unilateral nephrectomy is an effective method for inducing experimental diabetic nephropathy in the 'resistant' C57Bl/6J mouse strain.Chronic bilateral renal denervation reduces cardiac hypertrophic remodelling but not β-adrenergic responsiveness in hypertensive type 1 diabetic rats.Therapeutic effects of injection combined with telmisartan in patients with diabetic nephropathy by influencing collagen IV and fibronectin: A case-control study
P2860
Q26749412-F4523CEA-15A9-4283-9DA6-E3FD015990B2Q28079134-7258EC67-46CF-4A89-9881-940E6FD50AFAQ31149253-2F04D948-CEED-4F5D-A1BA-D06B79B12550Q33603428-24A5C914-8E6D-41CE-879C-4BCF741D99F0Q34080800-3F733208-0020-4531-B991-4E0E32677D06Q34367664-A0BF0F57-E8EF-4E24-B2B9-5FB5DCE3872BQ35025285-1E595AE4-42C3-40A9-BC7E-DF5A6B1EC062Q35077449-2A2E9860-51AF-497C-8454-FA21D9C9BCF7Q35224446-A14D1A3D-F30A-4BCB-8FC8-801BEB80914BQ35612928-B300BE13-8314-491C-85FD-AC58D421F713Q35880186-368C6648-62D5-4953-9E27-4EFEB4B2DAD6Q35953909-71377389-CD7D-48B9-AF04-90BF1481344AQ36142232-6B8242B2-1EC0-4903-BC98-7587C9F6F918Q36163016-334148E2-9C54-4A6D-8146-9619750E0617Q36406821-A1AD0702-59AA-4668-9FAB-F8404FBE6F3CQ36515043-78E17491-C6B5-4136-899F-C86D6C90DEF6Q36831100-7CCDCE67-BE80-4C96-A941-3CDDA222A093Q37055066-10D32712-B884-438A-8C26-B506BF78D2CBQ37869820-48F42D30-16FA-476D-B746-9B8B4EAAC84DQ38130262-8B2D4915-1BC1-4EAE-AA41-DA24C3BFE11CQ38378906-CAD79FD6-61EA-467F-B4D6-2365FD5B9C94Q38596700-C2673D48-99E3-4282-82D3-F5FD79606EACQ40965113-344174AC-7AC2-4A17-9642-EFF90CBCF9D3Q41598169-12B80539-C59B-4DEE-B2DC-9B6F0AEACABFQ41957292-5969B303-42B1-4651-92E4-8BAB3AB629DFQ45325842-BE83AECC-0BF3-420A-85FF-EDEF6C0921BBQ46270359-3B2A5CCD-C884-45A9-85B5-C766366FC880Q49048863-0C869C74-863F-4E63-882A-D789B4AC5EA2Q51270345-B0F626DC-FE2A-4E50-9834-49B400AA93CFQ52608853-8A2FFAAE-6885-4D21-A222-DD330C9C4C3DQ53540031-38412944-C2FA-44F1-8828-AF66B6D52558Q58704538-3CD13633-5A07-46D5-8A44-B9E8431A3C3E
P2860
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.
@en
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.
@nl
type
label
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.
@en
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.
@nl
prefLabel
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.
@en
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.
@nl
P2860
P1476
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.
@en
P2093
Peter N Van Buren
Robert Toto
P2860
P356
10.1053/J.ACKD.2010.10.003
P577
2011-01-01T00:00:00Z